Clinical trials: Anlotinib
Breast Cancer
Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients
vinorelbine are one of the main chemotherapy drugs used in the treatment of advanced breast cancer. It is available in oral form, making it convenient to use and an ideal choice for rhythmic chemotherapy.
- Trial name
- NCT06015126
- Testing
- metronomic oral vinorelbine plus anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yan Xue
Gastric Cancer, Gastroesophageal-junction Cancer
Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes
Abstract Study title: Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on…
- Trial name
- NCT05608785
- Testing
- IBI315, Oxaliplatin, Capecitabine
- Volunteers
- 45 people
- Sponsor
- Henan Cancer Hospital
Esophageal Neoplasms
Anlotinib Retrospective Study for Esophageal Cancer
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal…
- Trial name
- NCT05303740
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Feng Wang
Mesothelioma, Malignant, Mesothelioma, Malignant Pleural
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma.
- Conditions
- Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
- Trial name
- NCT05188859
- Testing
- Sintilimab+Anlotinib+Pemetrexed+Cisplatin
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Small Cell Lung Cancer Limited Stage
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
This study is a randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell…
- Trial name
- NCT06469879
- Testing
- TQB2450+Anlotinib
- Where
- 16 sites in China
- Volunteers
- 358 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
SCLC, Extensive Stage, Lung Cancer
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
To evaluates the effectiveness and safety of Toripalimab combined with Anlotinib and chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Toripalimab combined with Anlotinib.
- Conditions
- SCLC, Extensive Stage, Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04731909
- Testing
- Toripalimab, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Third Military Medical University
Small Cell Lung Cancer Extensive Stage
A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)
This retrospective real-world study aims to evaluate the efficacy and safety of anlotinib hydrochloride combined with immunotherapy as maintenance therapy following standard chemoimmunotherapy in extensive-stage small cell lung…
- Trial name
- NCT06982287
- Volunteers
- 100 people
- Sponsor
- Yong Fang
NSCLC, Tislelizumab
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in…
- Conditions
- NSCLC, Tislelizumab, Anlotinib, Nab-paclitaxel
- Trial name
- TitAN (NCT07089199)
- Testing
- neoadjuvant therapy, Surgery, Adjuvant therapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Qilu Hospital of Shandong University
NSCLC
Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of Anlotinib (AL3818) combined with pembrolizumab (MK-3475) in treatment-naïve adults with no prior systemic therapy for advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT04164745
- Testing
- Anlotinib, oral capsule, Pembrolizumab
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Peking Union Medical College Hospital
Ovarian Cancer Recurrent
Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.
Ovarian cancer is one of the three major malignant tumors of the female reproductive system. Even if newly diagnosed ovarian cancer patients undergo ideal tumor cell reduction surgery and postoperative chemotherapy, 70% to 80% of…
- Trial name
- NCT06660511
- Testing
- Disitamab Vedotin in Combination With Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Xiangya Hospital of Central South University
Platinum-resistant Recurrent Ovarian Cancer
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.
- Trial name
- NCT04720807
- Testing
- Letrozole combined with anlotinib hydrochloride
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if cadonilimab combined with anlotinib can be a safe and effective neoadjuvant therapy in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06426797
- Testing
- Cadonilimab plus anlotinib
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression
To evaluate the efficacy and safety of anlotinib combined with TQB2450 and the SOX regimen as first-line treatment for advanced gastric cancer with low PD-L1 expression
- Trial name
- NCT06939452
- Testing
- anlotinib +TQB2450 + Oxaliplatin+S-1
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Yongxu Jia
Gynecological Cancer
A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
This is a single-arm, open-label, phase II clinical trial to evaluate the efficacy and safety of penpulimab combined with anlotinib in subjects with gynecological cancer, including 23 ovarian cancer，37 endometrial cancer，26…
- Trial name
- ALTER-GO-020 (NCT05028504)
- Testing
- Penpulimab, Anlotinib
- Where
- 6 sites in China
- Volunteers
- 86 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Non Small Cell Lung Cancer
Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment
EGFR T790M gatekeeper mutation accounts for approximately 60% of acquired resistance to the first- or second-generation EGFR-TKI treatment.
- Trial name
- NCT04438902
- Testing
- osimertinib mesylate tablets and anlotinib hydrochloride capsules
- Where
- 2 sites in China
- Volunteers
- 3 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Advanced Renal Cancer
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.
- Trial name
- NCT04523272
- Testing
- TQB2450, Anlotinib, Sunitinib
- Where
- 39 sites in China
- Volunteers
- 528 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Extensive Stage Small Cell Lung Cancer
Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer
This is a the researchers launched a multicenter, prospective, single arm phase II clinical study, the group always had at least two cycle line standard platinum-based treatment and curative effect for SD, at least 6 months…
- Trial name
- NCT04933175
- Testing
- Fluzoparil, Anlotinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Liu Zhenhua
Non-Small Cell Lung Cancer Stage III
Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）
Evaluate the efficacy and safety of Anlotinib following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer
- Trial name
- ALTER-L029 (NCT03743129)
- Testing
- Anlotinib
- Where
- 4 sites in China
- Volunteers
- 90 people
- Sponsor
- Anhui Shi, MD
Desmoid
Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor
Thirty patients with desmoid tumors (invasive fibromatosis) will be recruited in the Department of Bone and Soft Tissue, Henan Cancer Hospital.
- Trial name
- NCT05490667
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
NSCLC, Angiogenesis
The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy
Immunotherapy has made a major progress in Lung cancer.However, challenges such as primary and acquired resistance, small fraction of benefit population and lack of predictive and prognostic biomarkers even exist.
- Conditions
- NSCLC, Angiogenesis, Immunotherapy
- Trial name
- NCT04670107
- Testing
- Anlotinib in combination with Immune checkpoint inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of Qingdao University